THE ROLE OF THE APO-B/APO-A-I RATIO IN THE COURSE OF CORONARY HEART DISEASE
Keywords:
atherosclerosis, coronary heart disease, atherogenic and anti-atherogenic lipoproteins,apo-B/apo-A-I ratioAbstract
Purpose of the study: to study the role of apoproteins of atherogenic and antiatherogenic lipoproteins (LP), as well as the ratio (R) of apo-B / apo-A-I in patients with coronary heart disease (CHD), angina pectoris FC II-III. Materials and methods:100 patients diagnosed with coronary artery disease; exertional angina FC II-III were examined. The average age of patients was 63.3±13.4 years. Of the examined patients, 43% were men, women accounted for 57%. All patients were determined their blood lipid spectrum, the level of the main apoproteins apo-AI, apo-B, and the R of apo-B/apo-A-I was also calculated. Results: The content of LDL was 3.6±0.1, which corresponds to the borderline level of CVD risk. In the general study group, the ratio of apo-B/apo-A-I was 1.31±0.01 and was in the zone of high risk of developing CVD. The prevalence of subclinical hypothyroidism was 3 times higher in the group of examined women than in men and amounted to 28.1% and 9.3% respectively. Conclusion. An increase in the ratio of concentration of the main apoproteins of atherogenic and antiatherogenic LP apo-B/apo-A-I is observed in both groups of studied patients and increases with the severity of the patients' condition (presence of concomitant hypertension, diabetes, hypothyroidism, obesity, hypodynamia). The study of the content of LDL in IHD angina pectoris in the examined patients corresponds to the borderline level of risk of developing CVD. In the general study group, R apo-B/apo-A-I was at a high risk of developing CVD.
References
Asvold B.O., Vatten L.J., Nilsen T.I., Bjøro T. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study // Eur. J. Endocrinol. 2007. Vol. 156(2). P. 181–186 (33).
Blankstein R, Budof f MJ, Shaw LJ, Gof DC Jr, Polak JF, Lima J, Blumenthal RS, Nasir K. Predictors of coronary heart disease events among asymptomatic persons with low-density lipoprotein cholesterol MESA (Muli-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2011; 58 (4):364-74.
El Harchaoui K, van der Steeg WA,Stroes ES, Kuivenhoven JA, Otvos JD, Wareham NJ, Hutten BA, Kastelein JJ, Kbaw KT Boekboldt SM. Value of low density lipoprotein paeticle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;49(5):547-53.
Gazi IF, T simihodimos V, T selepis AD, Elisaf M, Mikhailidis DP. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther. 2007; 7(1):53-72.
Iqbal A., Jorde R., Figenschau Y. Serum lipid levels in relation to serum thyroid stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromso Study // J. Intern. Med. 2006. Vol. 260. P. 53.
Koba S, Yokota Y, Hirano T, Ito Y, Ban Y, T sunoda F, Sato T, Shoji M, Suzuki H, Geshi E, Kobayashi Y, Katagiri T. Small LDL-cholesterol is superior to LDL-cholesterol for determining severecoronary atherosclerosis. J Atheroscler Thromb. 2008;15(5):250-60.
Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol.2011;5 (2):105-13.
Prieur X., Huby T., Coste H. et al. Thyroid hormone regulates the hypotriglyceridemic gene APOA5 // J. Biol. Chem. 2005. Vol. 280. P. 2753–2743.
Rodondi N., den Elzen W.P., Bauer D.C. Subclinical hypothyroidism and the risk of coronary heart disease and mortality // JAMA. 2010. Vol. 304(12). P. 1365–1374.
Srisawasdi P, Vanavanan S, Rochnawutanon M, Pornsuri yasak P, Tantrakul V, Kruthkl K, Kotani K. Heterogeneous properties of intermediate – and low density lipoprotein subpopulations. Clin Biochem 2013;46(15):1509-15.
Tsimihodimos V, Karabina SA, Tambaki A, Bairaktari E, Achimastos A, Tslepis A, Elisaf M. Effect of atorvastatin on the concentration, relative distribution, and chemical composition of lipoprotein subfractions in patients with dyslipidemias of type IIA and II B. J Cardiovasc Pharmacol. 2003;42(2):304-10.
Utkina EA, Afanaseva OI, Yezhov MV, Artemieva NV, Matcchin YuG, Bayda SM, Adamova IYu, Pokrovsky SN. Association between different lipoprotein subfractions and coronary aterosklerosis in middle-aged men on statin therapy. Cardiovestnik 2014; 1:68-6. Russian.
T.D. Chujinova, A.E. Degtyarev, T.D. Novikova Эффективность дозированном физическом нагрузки у пациентов с дислипидемиями. Seriya Meditsina. Farmatsiya. 2011 . № 10 (105).
